Results 221 to 230 of about 3,125,328 (279)

Biological Activities, Health Benefits and Synthesis of Equol and Its Derivatives: A Comprehensive Review

Food Science &Nutrition, Volume 14, Issue 1, January 2026.
Biological activities, health benefits and structures of equol and its derivatives. ABSTRACT Equol is a metabolite transformed from daidzein by intestinal microorganisms and has received extensive attention due to its various pharmacological activities and therapeutic potential.
Jiao‐Jiao Zhuo, Bing‐Juan Li, Meng‐Ran Tian   +2 more
wiley   +1 more source

CHK1 inhibition overcomes gemcitabine resistance in non-small cell lung cancer cell A549. [PDF]

Mol Cell Oncol
Ke ZY, Fu T, Wang XC, Ma X, Yin HH, Wang WX, Liu YJ, Liang AL.   +7 more
europepmc   +1 more source

Salvage Surgery for Primary Renal Pelvic Urothelial Carcinoma After Enfortumab Vedotin: A Case of Durable Remission With Nectin‐4 Loss

IJU Case Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Introduction Enfortumab vedotin is a standard therapy for advanced urothelial carcinoma, but its efficacy may be limited by acquired resistance and spatial heterogeneity of Nectin‐4 expression. Case Presentation We report the case of a 76‐year‐old woman with cT3N2M0 left renal pelvic urothelial carcinoma that was treated with first‐line ...
Takahito Wakamiya, Yuya Iwahashi, Hiroki Kawabata, Satoshi Muraoka, Shimpei Yamashita, Fumiyoshi Kojima, Yasuo Kohjimoto   +6 more
wiley   +1 more source

O-GlcNAcylation with ubiquitination stabilizes METTL3 to promoting HMGB1 degradation to inhibit ferroptosis and enhance gemcitabine resistance in pancreatic cancer. [PDF]

Mol Med
Wang Q, Wei D, Li C, Yang X, Su K, Wang T, Zou R, Wang L, Cun D, Tang B, Wu T.   +10 more
europepmc   +1 more source

Gemcitabine treatment causes resistance and malignancy of pancreatic cancer stem‑like cells via induction of lncRNA HOTAIR

, 2017
Li Wang, Ping Dong, Weiguo Wang, Mingquan Huang, Bole Tian   +4 more
openalex   +2 more sources

Hypoxia Triggers ALYREF‐Mediated m5C Methylation of KIF20A to Activate KIF20A/BUB1 for Generating Ferroptosis Resistance in Cervical Cancer Cells

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 1, January 2026.
ABSTRACT Ferroptosis resistance is a key player in cervical cancer (CC) development. Hypoxia is a negative factor affecting CC treatment by inducing ferroptosis resistance. Our study aimed to investigate the detailed mechanisms of hypoxia‐induced ferroptosis resistance in CC cells.
Yan Gao, Ting Zou
wiley   +1 more source

The Role of Macrophages in Cancer: From Basic Research to Clinical Applications

MedComm, Volume 7, Issue 1, January 2026.
Monocytes infiltrate the tumor microenvironment (TME) and differentiate into macrophages, which polarize into proinflammatory, antitumor M1 cells or immunosuppressive, protumor M2 cells. Within the TME, M2‐type tumor‐associated macrophages (TAMs) predominate and drive tumor growth, angiogenesis, and metastasis. Therapeutic strategies therefore focus on
Zhimei Liu, Yan Li, Jingchao Cao, Yefeng Qiu, Kun Yu, Shoulong Deng   +5 more
wiley   +1 more source

Targeting ALG3/FOXD1/BNIP3 Axis Prevents Mitophagy and Gemcitabine Resistance of Nasopharyngeal Carcinoma. [PDF]

Int J Biol Sci
Wang Z, Jin Y, He D, Zhu Y, Xiao M, Liu X, Cheng Y, Cao K.   +7 more
europepmc   +1 more source

Organoids in Cancer Research and Regenerative Medicine: Current Status, Challenges, and Future Prospects

MedComm, Volume 7, Issue 1, January 2026.
The management of cancer and tissue regeneration remains a substantial challenge to global health. Organoids, which are stem cell‐derived three‐dimensional multicellular structures, are revolutionizing biomedical research. Therefore, this review highlights their applications in cancer research and regenerative medicine, while discussing current ...
Ruiyang Li, Yuezhou Wu, Zhu'anzhen Zheng, Fengjin Zhou, Ke Xu, Jiacan Su   +5 more
wiley   +1 more source

Clinical Features and Treatment Strategies of Li‐Fraumeni Syndrome Patients With Inherited TP53 Mutations

Molecular Genetics &Genomic Medicine, Volume 14, Issue 1, January 2026.
LFS with TP53 disease‐causing mutations may be potential beneficiaries of immune checkpoint inhibitors and targeted therapies. Therefore, NGS and PD‐L1 testing should be performed in all LFS patients. ABSTRACT Background Li‐Fraumeni syndrome is a rare autosomal dominant disorder caused by a pathogenic mutation of the tumor suppressor gene TP53.
Keyu Chen, Yufen Xu, Binbin Song, Yuyang Gu, Xiaofang Xu, Jun Cao, Meiyu Fang   +6 more
wiley   +1 more source